Compare Kimberly Clark Corp (KMB) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Zimmer Biomet Holdings Inc — how do they compare? Kimberly Clark Corp trades at $109.35 (market cap $36.11B), while Zimmer Biomet Holdings Inc trades at $96.43 (market cap $18.55B). The key difference: Kimberly Clark Corp is the larger of the two by market cap, and Kimberly Clark Corp pays the higher dividend (4.72%). Which is the better fit depends on your goals.
| KMB | ZBH | |
|---|---|---|
Market Cap | $36.11B | $18.55B |
Sector | Consumer Staples | Health |
52-Week High | $134.81 | $107.71 |
52-Week Low | $93.05 | $79.58 |
Enterprise Value | $41.67B | $25.61B |
Dividend Yield | 4.72% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $109.47, up 1.34% today, with a neutral technical signal and bearish moving averages. Recent Q2 2026 earnings missed estimates due to China diaper disruptions and a distribution center fire, though gross margin expanded. The company maintains a strong dividend yield of 4.7% and an A credit rating. Analyst consensus is a $113.20 price target with 29% buy ratings, but near-term headwinds include softer consumer demand and inventory adjustments.
Outlook remains cautious with 2026 guidance trimmed; the stock offers value at a forward P/E of 14.6x and robust cash flow, but risks from China market volatility and input cost pressures persist. Institutional interest is mixed, with recent filings showing both new positions and trims. Long-term prospects hinge on innovation and productivity gains offsetting cyclical challenges.
ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
